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Obesityisknowntobeassociatedwithalargenumberoflong-termmorbidities,andwhileinsomecasestherelationshipofobesity
and the consequences is clear (for example, excess weight and lower extremity orthopedic problems) in others the mechanism is
not as clear. One common system of categorizing overweight in terms of the likelihood of negative consequences involves using
the concept of “metabolic syndrome”. We hypothesized that the development of a plasma protein proﬁle of overweight adolescents
withandwithoutthemetabolicsyndromemightgiveamorepreciseandinformativepictureofthediseaseprocessthanthecurrent
clinical categorization and permit early targeted intervention. For this paper, we used antibody microarrays to analyze the plasma
proteome of a group of 15 overweight female adolescent patients. Upon analysis of the proteome, the overweight patients diverged
from the nonoverweight female controls. Furthermore, the overweight patients were divided by the analysis into two population
clusters, each with distinctive protein expression patterns. Interestingly, the clusters were characterized by diﬀerences in insulin
resistance, as measured by HOMA. Categorization according to the presence or absence of the metabolic syndrome did not yield
such clusters.
1.Introduction
Thetermmetabolicsyndromeisusedtodescribeacollection
of factors associated with increased cardiovascular morbidi-
ties [1–10]. These risk factors can be clinically assessed by
conventional physical examination and laboratory tests. The
abnormalities can be grouped into the areas of obesity, lipid
dysregulation, insulin resistance, and cardiovascular abnor-
malities [11–13]. The most straightforward measurement is
the level of obesity which is usually quantiﬁed as the body-
mass index (BMI), although waist measurement or waist/hip
r a t i o sa r ea l s ou s e dt od e ﬁ n er i s k[ 14–16]. Dyslipidemia is
deﬁned as increased triglycerides, decreased high-density
lipoprotein (HDL) cholesterol concentrations in the blood
[17–19], and hypertension [20–22]. Decreased sensitivity to
insulin is perhaps the single central characteristic of the
syndrome [23–26]. Resistance to insulin eﬀects on glucose
metabolism may range from mild to severe. Other factors
seen in patients with the syndrome that contribute to
cardiovascular pathology include the proinﬂammatory and
procoagulatorystatesdisplayedbymanyaﬀectedindividuals.
While common, these factors are not usually included in the
strict deﬁnition of metabolic syndrome.
The incidence of obesity continues to rise, reaching 50%
or greater in many populations. Based on the current deﬁni-
tionofmetabolic syndrome, itwasestimatedin2002 byFord
et al. (Third National Health and Nutrition Examination
Survey (NHANES), [11]) that greater than 25% of the
American population could be considered to have metabolic
syndrome. A 2009 evaluation of the NHANES 2003–2006
data [27] conﬁrmed an ongoing increase in the numbers of
aﬀected individuals, with an overall percentage of Americans2 Human Genomics and Proteomics
adults classiﬁed as having metabolic syndrome at the time
of that survey, of 34%. This percentage increased with age,
going from 20.3% for adults 20–39 years old to 40.8% for
adults 40–59 years old and to 51.5% for adult over the age of
60 [27]. This is dismaying as it translates into twofold greater
risk of death from cardiovascular complications as well as
threetimesthelikelihoodofmyocardialinfarctionandstroke
forthese individuals whencomparedtoadults not diagnosed
with metabolic syndrome. Perhaps even more dismaying,
that same database estimated the incidence of obesity in
adolescents in the USA as 30%. Based on this data, it has
been estimated that the current generation of adolescents
may be the ﬁrst to have a shorter life expectancy than their
grandparents. It is clear that identifying and understanding
pathophysiologic factors leading to this grim projected
consequence is an important mandate.
We hypothesized that an analysis of the plasma proteome
from overweight girls might yield clues to the pathologic
process, before secondary and tertiary consequences of the
disorder were encountered. We further hypothesized that
the proteome from overweight subjects with the metabolic
syndrome would diﬀer from those without the complete
syndrome.
To test these hypotheses, we examined the proteomic sig-
nature of plasma from overweight girls, some with and some
without the clinical characteristics of the metabolic syn-
drome. We hoped that this would provide relevant informa-
tion on the disease process and might lead to novel avenues
of intervention and treatment.
2. Methods
2.1.PlasmaPreparation. Bloodfromobesefemaleadolescent
patients and healthy adult volunteers was collected in
accordance with a human use protocol approved by the
Institutional Review Boards of the Walter Reed Army Med-
ical Center, Washington, DC and the Uniformed Services
University of the Health Sciences, Bethesda, MD. Informed
consent was obtained from parent or guardian and assent
from the subjects themselves. To avoid possible interference
of lipid levels with subsequent assays, blood collection was
performedonfastingpatients.Bloodwascollectedusinga21
gauge butterﬂy needle into vacutainer tubes containing Acid
Citrate-Dextrose as the anticoagulant. Prostacyclin (Sigma-
Aldrich, St. Louis, MO) was added to the whole blood
to a ﬁnal concentration of 50ng/mL (stock solution was
50ug/mL in 50mMTris, 100mMNaCl, pH 12, stored at
−80◦C until use) to remove unactivated platelets. The blood
was ﬁrst centrifuged at 400RCF for 15min at 23◦C to pellet
the erythrocytes and leukocytes. The platelet-rich plasma
(PRP) was then removed, and prostacyclin was again added
to the PRP. The PRP was then centrifuged at 1800 RCF
for 20min at 23◦C to pellet the platelets. The plasma was
removed and frozen in liquid nitrogen until analyzed.
2.2. Clinical Assessment of Adolescent Volunteers. Overweight
adolescents presenting for evaluation and treatment were
recruited for this study as part of a larger study of adolescent
obesity. The deﬁnition for metabolic syndrome was based on
BMI, HOMA, triglyceride levels, blood pressure, and HDL
levels. Subjects that met three or more of the following
criteria were classiﬁed as having metabolic syndrome:
BMI greater than 85th percentile for age (see CDC website
http://www.cdc.gov/healthyweight/assessing/bmi/childrens
bmi/about childrens bmi.html and Freedman et al. [28]);
HOMA greater than 3.16 or fasting glucose greater than
109mg/dL or 2-hour oral glucose test greater than
139mg/dL; triglycerides greater than 95th percentile for
age; blood pressure greater than 95th percentile for age and
height [29] or HDL less than 40mg/dL.
2.3. Antibody Microarray Assay. Protein proﬁles of patient
and control plasma samples were analyzed with Clontech
Antibody Microarray 500 (Mountainview, CA). Each slide
contains 507 antibodies printed in duplicate (see web-
site: http://bioinfo.clontech.com/abinfo/initialize.do#; cat #
63q790, lot # 8123984, for complete list of antibodies
printed).PlasmasampleswerelabeledwithCY3(GEHealth-
care, CA) and a bronchial epithelial cell line that was used
as a quality control standard was labeled with CY5 (GE
Healthcare). Excess dye was removed with PD10 desalting
columns. The samples were combined in a ratio of 80ug
plasma: 20ug cell lysate and incubated with the Clontech
microarray according to manufacturer directions (Clontech
protocol PT3648-1). More protein was used for the plasma
samples than the lysate because of the high proportion of
protein in the plasma that was albumin. Following labeling,
the slides were scanned in a Perkin Elmer ScanArray HT
microarray scanner (Waltham, MA) at 90% laser power,
50VPMT, and focus position 0.
2.4.BioinformaticsforAnalysisofAntibodyMicroarrays. Data
from scanned microarrays were loaded into the Perkin Elmer
Express analysis software. Markers and control spots were re-
moved. Only spots with a signal-to-noise ratio greater than 2
were used. Any duplicate spots that were diﬀerent by greater
than20%werediscarded(approximately16%oftotalspots).
The remaining spots were normalized to the median, and
the ratio of plasma/control lysate for each antibody was cal-
culated. This ratio was used to compare the relative abun-
dance of each protein between samples.
Two software tools were used to analyze the protein ex-
pression data. First, cluster analysis was performed to deter-
mine hierarchical clustering and groupings of samples with
similar levels of protein expression (Cluster and Treeview,
MB Eisen, http://rana.lbl.gov/EisenSoftware.htm). Unsuper-
vised clustering analysis divided the donors into three
groups: controls and two sets of patients. Using these group-
ings, pathway analyses and examination of interactions bet-
weenthepatientproteinsetswereperformedusingIngenuity
Pathway Analysis (Ingenuity Systems, Inc., Redwood City,
CA). Patient/control ratios were calculated for each protein
on the array and the two patient groups were compared for
expression in the canonical pathways.
For this pilot study, only three control samples were ana-
lyzed. This is a low number of samples, and, for future work,
the goal is to analyze 100 patient and 100 age-matched con-
trol plasmas.Human Genomics and Proteomics 3
Table 1: Patient demographics. Study subjects were recruited from
patients referred to the Pediatric endocrinology clinic at the Walter
Reed Army Medical Center. Patients entered into the study were
givenaroutinehealthassessmentandaBodyMassIndex(BMI)was
calculated. A glucose tolerance test was administered and insulin
sensitivity/resistance was determined and calculated as HOMA
value. Controls were normal adult women volunteers. FMS: female
metabolic syndrome patient (3 or 4 factors), FOb: female obese
patient (fewer than 3 factors), FC: female control.
Classiﬁca-
tion
Patient
number
No. of
factors
Age
(years) BMI HOMA HDL TG
FMS 17 4 17 34.9 4.68 64 137
FMS 18 3 13 35.3 10.8 35 88
FMS 23 3 15 31.7 2.64 19 137
FOb 32 2 13 28.8 2.8 47 183
FOb 10 2 17 42.6 2.9 38 31
FOb 19 1 13 26.7 2.68 67 96
FOb 22 2 16 35.6 3.41 46 93
FOb 24 2 13 27.8 5.74 40 98
FOb 25 2 15 33.9 7.03 50 112
FOb 29 2 16 45.5 8.46 44 73
FOb 31 2 15 29 3.2 58 70
FOb 34 2 14 37.6 6.49 46 87
FOb 35 2 13 29 3.19 56 61
FOb 36 2 13 36 7.23 53 69
FOb 38 1 16 32.9 3.01 68 92
FC 3 1 38 21.3 Na Na Na
FC 5 1 34 20.6 Na Na Na
FC 8 1 33 Na Na Na Na
3. Results
3.1. Patient Demographics. Fifteen overweight adolescent
girls with ages ranging from 13 to 17 years old (14.6 ±
1.5 y.o.) were recruited for the study. Their BMI ranged
from 26.7 to 45.5 (33.8 ± 5.4). Exclusion criteria included
frank diabetes or the use of any drug known to aﬀect
bloodpressure,lipidproﬁle,orcarbohydratemetabolism.All
subjects were otherwise in good health. The demographic
information is summarized in Table 1. From these data, we
identiﬁed three clinical subgroups: (i) female controls (FC),
(ii) obese adolescent females displaying fewer than three of
the accepted metabolic syndrome criteria (Fob), and (iii)
obese adolescent females with three or more of the metabolic
syndrome criteria (Fms).
3.2. Supervised Proteomic Analysis, Based on Preidentiﬁed
Clinical Subgroups. Table 2 identiﬁes proteins that are dis-
tinct to each of the three identiﬁed clinical subgroups
referred to in the demographic descriptions. The analytic
workﬂow consists of the following steps: (i) Firstly, the ratio
of the patient sample/control cell lysate for each of 507
antibodies on the array is calculated to give a unique value
for that speciﬁc protein. (ii) Secondly, the values are then
averaged for the patients within each of the three clinically
Low HOMA
High HOMA
Controls
31-Fob
22-Fob
35-Fob
10-Fob
17-Fob
38-Fob
19-Fob
24-Fob
34-Fob
29-Fob
36-Fob
8-Fc
5-Fc
3
3
2
1
-Fc
32-Fms
23-Fms
25-Fms
18-Fms
Figure 1: Cluster diagram representing plasma protein expression
levelsoffemalepatientandcontroldonors.Unsupervisedclustering
(Figure 1) separated the patients into two groups. Comparison of
the patients in these groups to the clinical values revealed that
the clustering correlates well with the HOMA values. Patients that
clusteredinwhatwedesignatedtheHighHOMAgrouphadHOMA
values greater than 4.0 except for patients nos. 19 and 38 (7/9). All
patients in the Low HOMA group had values less than 4.0. Based
on a visual inspection on the cluster diagram, two regions of the
protein set stood out as showing particular distinction between the
groups. These proteins are in the two regions marked region 1 and
region2onthediagram.Positivevaluesrepresentbindingincreased
relative to the protein standard and show up as red on the diagram,
while values that are negative represent decreased protein binding
and show up as green on the diagram.
deﬁned sub-groups. (iii) Thirdly, the ratio of Fob/Fc and
Fms/Fc for each antibody is calculated to assess the average
diﬀerence in expression for each protein between the groups.
(iv) Finally, using Ingenuity Pathways Analysis software
(IPA), the data are analyzed by searching for proteins that
exhibit increased expression in only the Fob/Fc comparison
or only the Fms/Fc comparison. The rationale is that this
protein proﬁle would help deﬁne the diﬀerences between
patients who are obese, but do not have the complete
metabolic syndrome, and patients who ﬁt the clinical def-
inition of metabolic syndrome. Using this methodology,
Table 2 shows that 21 unique proteins can be identiﬁed that
distinguish Fob from Fc, and 29 proteins can be identiﬁed
that can distinguish Fms from Fc. The supervised approach
has the advantage of identifying those proteins whose ex-
pressions most correlate with clinical impression.
3.3. Unsupervised Proteomic Analysis, without Reference to
Preidentiﬁed Clinical Subgroups. An alternative approach is
to determine if there is a speciﬁc proteomic signature that
distinguishes between patients with metabolic syndrome,
and those patients that are simply obese. Our strategy has4 Human Genomics and Proteomics
Table 2: Study subjects were classiﬁed as either obese but not metabolic syndrome or obese with metabolic syndrome based on the clinical
ﬁndings and compared to the control subjects. Proteins were identiﬁed that had expression levels that were at least 1.5-fold diﬀerent between
the controls and the obese patients or between controls and metabolic syndrome patients (either upregulated or downregulated). Table 2(a)
shows proteins with expression levels signiﬁcantly altered only in FMS compared to FC. Table 2(b) shows proteins with expression levels
signiﬁcantly altered only in Fob compared to FC. Table 2(c) shows proteins with expression levels signiﬁcantly altered only in both FMS and
F o bc o m p a r e dt oF C .F o l dc h a n g e sa n dP values relative to the controls are listed.
(a)
Fold change Entrez gene name P-value
3.192 Interleukin 3 (colony-stimulating factor, multiple) 3.49E −02
2.404 Interleukin 13 3.36E −02
2.133 Caspase 9, apoptosis-related cysteine peptidase 1.21E −02
2.13 Protein kinase N2 1.12E −02
2.046 Adenomatous polyposis coli 6.91E −03
1.976 Disabled homolog 2, mitogen-responsive phosphoprotein (Drosophila) 8.04E −03
1.799 Nuclear factor of activated T cells, cytoplasmic, calcineurin-dependent 1 6.39E −03
1.764 RAS p21 protein activator (GTPase activating protein) 1 4.90E −03
1.732 Caldesmon 1 3.24E −02
1.714 RAP1A, member of RAS oncogene family 3.13E −03
1.647 Nonmetastatic cells 1, protein (NM23A) expressed in 1.66E −02
1.604 Diablo homolog (Drosophila) 4.60E −02
1.572 GRB2-related adaptor protein 2 1.90E −02
−1.619 Signal transducer and activator of transcription 6, interleukin-4 induced 3.57E −06
−1.621 Epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) 1.48E −03
−1.628 Reversion-inducing-cysteine-rich protein with kazal motifs 2.57E −03
−1.635 Tumor necrosis factor (TNF superfamily, member 2) 2.81E −03
−1.637 Tight junction protein 1 (zona occludens 1) 8.31E −05
−1.655 V-erb-b2 erythroblastic leukemia viral oncogene homolog 2 1.37E −02
−1.722 Mitogen-activated protein kinase kinase 5 1.57E −02
−1.724 Conserved helix-loop-helix ubiquitous kinase 1.64E −03
−1.736 Tumor protein p53 6.75E −03
−1.842 Chromogranin A (parathyroid secretory protein 1) 2.27E −04
−1.842 Eukaryotic translation initiation factor 4E 1.16E −03
−1.913 Minichromosome maintenance complex component 6 8.38E −05
−1.929 Glutamate receptor, ionotropic, N-methyl D-aspartate 2B 4.98E −07
−2.052 Centrosomal protein 250kDa 9.46E −05
−2.142 Caspase 4, apoptosis-related cysteine peptidase 2.48E −08
−3.224 Diaphanous homolog 1 (Drosophila) 2.80E −03
(b)
Fold change Entrez gene name P-value
2.249 Myeloid cell leukemia sequence 1 (BCL2-related) 4.93E −02
1.896 Retinoblastoma-like 2 (p130) 3.05E −07
1.769 Caveolin 1, caveolae protein, 22kDa 4.10E −06
1.728 DEAD (Asp-Glu-Ala-Asp) box polypeptide 1 7.47E −05
1.725 Protein kinase C, beta 7.56E −07
1.716 E2F transcription factor 1 5.22E −04
1.69 CD28 molecule 7.36E −04
1.651 Son of sevenless homolog 1 (Drosophila) 1.16E −03
1.617 Colony stimulating factor 1 receptor 2.19E −06
1.588 Protein tyrosine phosphatase, nonreceptor type 6 1.03E −03
1.574 A kinase (PRKA) anchor protein 1 4.69E −06
1.539 General transcription factor Iii 7.23E −05Human Genomics and Proteomics 5
(b) Continued.
Fold change Entrez gene name P-value
1.536 Casein kinase 1, epsilon 8.53E −03
1.535 Junction plakoglobin 5.09E −08
1.509 Adaptor-related protein complex 3, mu 1 subunit 2.96E −03
1.502 Cyclin-dependent kinase inhibitor 1A (p21, Cip1) 4.90E −04
1.501 Proteasome (prosome, macropain) 26S subunit, ATPase, 5 5.18E −03
1.729 Platelet-derived growth factor receptor, beta polypeptide 1.30E −02
−1.512 Cyclin-dependent kinase inhibitor 1C (p57, Kip2) 5.60E −03
−1.553 Chromodomain helicase DNA-binding protein 3 3.57E −03
−1.686 Glycogen synthase kinase 3 beta 3.13E −03
(c)
Fold change Entrez gene name P-value
Fob FMS
2.301 −1.578 Androgen receptor 3.84E −03
2.133 1.814 Insulin-like growth factor binding protein 3 1.31E −02
1.95 2.13 Protein kinase N2 9.92E −03
1.746 2.398 Transcription elongation regulator 1 4.43E −03
1.622 1.614 SWI/SNF related, matrix associated, actin-dependent regulator of chromatin 6.15E −03
1.612 1.875 Erythrocyte membrane protein band 4.9 (dematin) 1.08E −03
1.608 −1.722 Mitogen-activated protein kinase kinase 5 5.09E −05
1.554 −1.684 Interleukin 1, beta 5.54E −04
−1.862 −1.691 Ribosomal protein S6 kinase, 70kDa, polypeptide 1 2.22E −06
−13.41 −5.309 Spleen focus forming virus (SFFV) proviral integration oncogene spi1 3.92E −06
therefore been to subject the data to analysis using a con-
ventional hierarchical cluster algorithm [30], without con-
sideration for any of the clinical information associated
with each patient. Figure 1 shows data analyzed in this
manner. Examination of the results shows that the control
samples separate into a grouping that is distinct from the
obese patient samples. The samples identiﬁed as metabolic
syndromepatientsdonotformaseparategroupingalthough
the Fms samples do form two closely placed pairs. However,
samples with high homeostatic model assessment (HOMA)
values, regardless if they are identiﬁed as Fob or Fms, do
separate from the patients with low HOMA. HOMA is the
product of glucose and insulin concentrations, normalized
to a constant, and is a conventional measure of insulin
resistance [31]. The regions labeled 1 and 3 on the cluster
diagram illustrate very clearly how the protein expression
levels of the proteins separate the patient population into
two distinct populations. The proteins contained in segment
1 are shown in Table 3. Together, the proteins in those two
segments included 201 of the 507 proteins surveyed on
the microarray. This alternative, unsupervised approach to
identifying a proteomic signature for metabolic syndrome
thereforesuggeststhatinsulinresistancemaybeauniquefac-
tor, correlating with a speciﬁc pattern of protein expression.
3.4. Functional Analysis of the Insulin Receptor Signaling Path-
way in Metabolic Syndrome Patients. The unsupervised ap-
proach to data analysis suggests that insulin resistance plays
a key role in structuring the proteomic signature for meta-
bolic syndrome. We therefore used the expression levels of
the proteins identiﬁed by the hierarchical cluster algorithm
to investigate the insulin receptor signaling pathway in the
metabolic syndrome patients. As shown in Figure 2, the
pathway has three major branch points leading from the
receptor. Initially ten signal transduction pathways lead out
from the receptor. Two of these pathways, SOS (“son of
sevenless”, Ras binding protein) and IRS1 (insulin receptor
substrate), will lead to downstream transcription control.
Furthermore, SHP2 (tyrosine phosphatase) and JNK1 (ser-
ine/threonine kinase) can inhibit the IRS1 transcription
pathway. If IRS1 is not inhibited, this pathway will eventually
activateAKT(serine/threoninekinase,alsoknownasprotein
kinase B, PKB) and lead to transcription events that can
inﬂuence cell growth or apoptosis. AKT also will inhibit and
act on the mTOR and GSK3 pathways of protein synthesis.
SOSwillacti vat etheRaspath wa ywhic hc onnectst oMEK1/2
and ERK1/2 which will also mediate transcription and cell
growth. The third major pathway leading from the insulin
receptorconnectstotheglucosetransporterGLUT4pathway
where the composition of lipid rafts and the mechanics of
vesicle formation may be altered. Because all of the proteins
from the antibody arrays are screened against the canonical
pathways, both the low HOMA and the high HOMA groups
had same elements in the insulin receptor pathway [23].
However, the high HOMA group had three proteins that
were strongly depressed in expression compared to the
controls (H-Ras, elF4E, and PKCH, see Table 3) and one that6 Human Genomics and Proteomics
Table 3: Protein composition of region 1 from the cluster diagram (Figure 2). Unsupervised clustering (Figure 1) separated the patients into
two groups. Based on a visual inspection on the cluster diagram, two regions of the protein set stood out as showing particular distinctions
between the groups. These proteins are in the two regions marked region 1 and region 3 on the diagram in Figure 1. The values listed are
derived from the ﬂuorescent values representing protein binding on the antibody microarray. Positive values represent binding increased
relative to the protein standard and show up as red on the diagram, while values that are negative represent decreased protein binding and
show up as green on the diagram. The values for the entire 507 proteins on the microarrays are displayed in supplemental Table 1S available
online at doi:10.4061/2011/323629.
Unique ID Protein name Low HOMA Diagram color High HOM Diagram color Control Diagram color
331 hILP/XIAP 0.3121 Red −0.1620 Green Red
4927 Nup88 0.2371 Red −0.4194 Green 0.0196 Red
9001 HAP-1 0.2739 Red −0.3215 Green 0.0214 Red
4288 Ki-67 0.1811 Red −0.3101 Green 0.1144 Red
7124 TNFa 0.2171 Red −0.3622 Green 0.0082 Red
6732 SRPK1 0.2904 Red −0.2250 Green 0.1255 Red
2064 erbB-2/HER-2 0.2099 Red −0.2043 Green 0.1434 Red
60412 rSec8 0.2539 Red −0.3078 Green 0.0849 Red
6550 NHE-3 0.1830 Red −0.2553 Green 0.3126 Red
8828 Neuropilin-2 0.2417 Red −0.3104 Green 0.0044 Red
7157 p53 0.1745 Red −0.2634 Green −0.0183 Green
821 Calnexin 0.1376 Red −0.2462 Green Red
4301 AF6 0.0948 Red −0.3060 Green −0.1052 Green
1263 Fnk 0.1443 Red −0.3505 Green −0.0640 Green
1977 eIF-4E 0.2086 Red −0.2965 Green 0.0760 Red
3265 Ras (Ha) 0.1629 Red −0.3541 Green 0.0564 Red
5577 PKA rIIb 0.2566 Red −0.1664 Green −0.0637 Green
482 Na+/K+ ATPase b2 0.0594 Red −0.3157 Green Red
837 Caspase-4/TX ICH-2 0.1421 Red −0.3325 Green 0.0000 Green
5922 Gap1m 0.0999 Red −0.3312 Green −0.0447 Green
2280 FKBP 12 0.0520 Red −0.3316 Green −0.0258 Green
8434 RECK 0.0555 Red −0.2946 Green −0.0702 Green
1263 PRK 0.0568 Red −0.3597 Green 0.0095 Red
1113 Chromogranin A 0.0825 Red −0.2857 Green 0.1098 Red
136319 V-1/myotrophin 0.2074 Red −0.3630 Green 0.0316 Red
6778 Stat 6 0.3217 Red −0.3598 Green 0.0146 Red
4087 Smad2 0.2301 Red −0.1654 Green −0.0160 Green
394 p190 0.2663 Red −0.0975 Green Red
160 Adaptin a 0.0971 Red −0.3414 Green 0.1676 Red
3916 Lamp-1 −0.0467 Green −0.1003 Green 0.3199 Red
8717 TRADD 0.1246 Red −0.1444 Green Red
4436 MSH2 −0.0851 Green −0.1053 Green 0.2459 Red
53917 Rab24 −0.0712 Green 0.0840 Red 0.1473 Red
5079 Pax-5 −0.0179 Green 0.1400 Red −0.0893 Green
997 CDC34 0.0751 Red −0.2010 Green 0.0720 Red
5335 Phospholipase C γ1 0.0712 Red −0.2652 Green 0.0816 Red
4331 p36 0.2287 Red −0.1030 Green 0.0086 Red
10241 NDP52 0.3068 Red −0.1806 Green 0.1283 Red
4149 Max 0.2633 Red −0.0925 Green −0.0140 Green
857 Caveolin 1 0.3876 Red −0.1245 Green −0.0466 Green
309 Annexin VI 0.3409 Red −0.1283 Green −0.0005 Green
6921 SIII p15 0.3574 Red −0.0806 Green −0.1393 Green
1870 E2F-2 0.2694 Red −0.1281 Green 0.0770 Red
4841 p54nrb 0.2229 Red −0.0289 Green −0.1176 GreenHuman Genomics and Proteomics 7
Table 3: Continued.
Unique ID Protein name Low HOMA Diagram color High HOM Diagram color Control Diagram color
1981 eIF-4g 0.1675 Red 0.0356 Red −0.0793 Green
57448 BRUCE 0.1585 Red −0.1595 Green −0.0811 Green
940 CD28 0.2257 Red −0.1958 Green −0.1689 Green
4046 LSP-1 0.1895 Red −0.2442 Green 0.0870 Red
891 Cyclin B1 0.2257 Red −0.2798 Green 0.0347 Red
2752 Glutamine synthetase 0.2952 Red −0.1749 Green −0.0764 Green
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Figure 2: Canonical pathways for the insulin receptor. Protein expression levels for all patients were input into the Ingenuity Pathways
Analysis software for analysis of changes in relevant pathways. IPA software has 272 annotated canonical pathways to which it will ﬁt the
experimentalvaluesofproteinexpression.Usingthisanalysisfunction,itispossibletoseeif(1)theproteinsofinterestareinvolvedinspeciﬁc
pathways and (2) how the expression levels of those proteins may aﬀect the activity of the pathway. Proteins from our microarray data that
are present in the canonical scheme are shaded. If the ratio of patient to control is less than 1.5, the shading of the protein symbol is gray. If
the ratio is greater than 1.5, the symbol is red for an increase compared to the control and green for a decrease compared to the control. To
limit the pathways to a manageable number, for this analysis, we examined the pathway of insulin action and the pathway of NFκB activation
and compared how the two groups of patients diﬀered in their expression levels. The insulin receptor pathway was selected for display.
was strongly elevated (JNK1). In contrast, the low HOMA
group showed slightly elevated SOS1, ERK1/2, and JNK1/2
and slightly depressed RPS6K.
3.5. Functional Analysis of the NFκB Pathway in Metabolic
Syndrome Patients. Examination of the NFκBp a t h w a y
(Figure 3) revealed strong diﬀerences between the high
and low HOMA groups. Surprisingly, the molecules IL-1β
and TNF-α were decreased relative to the controls in
the high HOMA, whereas IL-1βwas slightly elevated in
the low HOMA set. From the stage of the IL-1β and
TNF-α cell surface receptors, the signal is passed through
a number of intermediate steps to phosphorylate the IKK
complex. The phosphorylated IKK complex will, in turn,
phosphorylate the inactive NFκBc o m p l e x .O u rr e s u l t s
show that the IKK subunits in the high HOMA were
altered but were not changed in the low HOMA group.
Changing the ratios of the various IKK subunits can
be expected to modify the NFκB complex processing,
translocation to the nucleus and, ultimately, transcription
patterns that could aﬀect inﬂammation and immune regu-
lation.8 Human Genomics and Proteomics
IL1B
IL18 IL1A
IL1F6
IL1F9
IL1RN
IL1F7
IL1F10
IL1F5
IL1F8
IL33
IL-1 TNF-
RANKL
GH
EGF BMP
2/4
NGP
KRAS
HRAS
MRAS
TGF- CD40L LTA BAFF
BR3 LTBR CD40 TNFR
TRAF2
TRAF
TRAP
TRAF TRAF
RIP
MEKK3/ NK
ds-RNA
PKR
I
I
NK I
L-1R/TLR
MYD88
IRAK-M
IRAK1/4
5/ 2/ 6 6 3/5
A20
TRAF6
FAK1 TAB1
TCR
LCK
Zap70
PLCv2
MB(2)
MB(2)
PKC
(β,8)
PRKCB
PRKCQ
MKK
6/7
JNK1
β-TrCP
NF- B1
NF B1
p50
p           50
P R C p300
p65/RelA
p65/RelA
Proteasomal
Proteasomal
degrad tion
processing
IKKα
IKKα
IKKβ IK K
AKT
Cot
β-TrCP
p52
p52
NF B2
NF 2
p52
NF B2
NF B
NF- B1
NF- B
NF- B2
p100
RelB
RelB
RelB
Alternate pathway
of NF and
activation
1.Inﬂammation
2.Immune regulation
3.Survival
4.Cell proliferation
1.Lymphogenesis
2.B cell maturation
DAC1/2
IKKα GSK-3β
PKc
CK
RRAS NRAS
RRAS2
Extracellular
Cytoplasm
Insulin
PK c A
UBE2N
UBE2V1
MALT1
BcI10 BIMP
p50/p52
2 p65/RelA
p65/RelA
p65/
/
RelA p65/RelA
Down
actor
receptor
TIRAP
PI3K
NAP1-NAK
Ras
High HOMA pathway
IκBI κB
IκB
κ
κ
κ
κ κ
κ
κ κ
κB
B
IκB
κ
ζ
αα
NF- Signali g n κB
γ
space
NF-κB pathway
a
e Nucl us
e Nucl us
(a)
IL1B
IL18 IL1A
IL1F6
IL1F9
IL1RN
IL1F7
IL1F10
IL1F5
IL1F8
IL33
IL-1 TNF-
RANKL
GH
EGF BMP
NGP TGF- CD40L LTA BAFF
TRAF2
CD40
TRAF
TRAP
BR3 LTBR
TRAF TRAF
RIP
MEKK3/
ds-RNA
PKR
MYD88
IRAK-M
IRAK
1/4 A20
TRAF6
FAK1 TAB1
LCK
Zap70
PLCv2
MB(2)
MB(3)
MB(3) MB(3)
MB(1)
PKC
(β,8)
MKK JNK1
β-TrCP
NF- B1
NF B
NF- B1
NF- B1
p50
p50
p65/RelA
Proteasomal
degra a d tion
IKKα
IKKα
IKKβ
AKT
Cot
β-TrCP
p52
NF- B2
Proteasomal
processing
p52
NF B2
NF- B2
p100
RelB
RelB
Alternate pathway
of NF and
activation
p52
NF- B2
RelB
1.Lymphogenesis
2.B cell maturation
phosphotransferase
Acceptor
CK2
Insulin
IRS2-PI3K
PIK3C2A PIK3C2G PIK3C2B
NF- B
1.Inﬂammation
2.Immune regulation
3.Survival
4.Cell proliferation
DAC1/2
5/6
6
5 3 2/ /
4 2/
IKKα GSK-3β
PKC
PK c A
PIK3R2
PIK3R3
SHP2-PI3K-GAB2
PIK3R5
PIK3R6
PIK3R1 PIK3CA
PIK3R4
PIK3CB
PIK3CD
PIK3CG
PIK3C3
p65/RelA
p65/RelA
p65/RelA
p65/RelA p65/RelA
Down
factor
receptor
TIRAP
NAP1-NAK
p50/p52
UBE2N
UBE2V1
MALT1
1 BcI10 BIMP
PI3K-PIP2-Src
PI3K p85
P110
Ras
Low HOMA pathway
α α
PI3K
IκB Iκ
κ
B
IκB
IκB
κ
κ κ
κ
κ
κ
κ
κ ζ
NK I
κB
Jnk JINK1/2
sapk
NF- signali g n κB
Cytoplasm
IL-1R/TLR
TCR TNFR
NK I
P B C p300
e Nucl us
IK K γ
Extracellular space
1.589
/
NF-κB pathway
(b)
Figure 3: Canonical pathways for NFκB. Changes in protein levels for High versus Low HOMA are shown as red for increased levels and
green for decreased levels.
Selecting subsets of the larger pathway, such as the
TNF-α/TNFR1 pathway or the IL-4 signaling pathway,
allows further examination of details of NFκB activation.
For example, by reviewing the TNF-α/TNFR1 pathway, it
was observed that IKKα decreased and IKKβ increased in
the high HOMA group but there are no signiﬁcance changes
in the low HOMA group. Another detail that is apparent
with the higher resolution examination is that the apoptotic-
inducing enzyme, caspase 9, is increased in the high HOMA
group and not in the low HOMA group. Close examination
of the IL-4 pathway also shows changes in NFATC 1 and 2
(nuclear factor for activated T cells) in the low HOMA group
but not in the high HOMA group.
4. Discussion
These data show that a subset of overweight girls exhibits
a speciﬁc proteomic signature in plasma, and that the dis-
crimination made by the proteomic analysis is most closely
associated clinically with the HOMA value. The potential
importance of this ﬁnding is echoed by the results of analysis
of the components of the insulin receptor pathways. If this
characteristic,insulinresistance,isthemostimportantfactor
dividing the overweight girls into two groups, it may be
that we should be emphasizing the identiﬁcation of insulin
resistanceastheprimarygoalintheevaluationofoverweight
adolescents. Further it may be that therapeutic interventions
should be targeted speciﬁcally to this improving insulin
sensitivity, rather than concentrating, as we do, on weight
loss as the major goal of interventions. This is particularly
important as there are interventions, such as exercise,
that may improve insulin sensitivity without necessarily
decreasing BMI.
4.1.AnalysisofthePlasmaProteomeBasedonClinicalCriteria
Alone. For the analysis in this paper, two approaches were
employed. For the ﬁrst approach, we grouped our patients
according to clinical criteria. Study subjects were classiﬁed
as either overweight without metabolic syndrome or over-
weight with metabolic syndrome based on the clinical ﬁnd-
ings. The two categories were then compared to the control
subjects. Working on the hypothesis that diﬀerential protein
expression could separate the two classes of obese subjects
into distinct groups, the proteome was screened for proteins
that were altered from the control values by at least 1.5-fold
in the obese group or the obese/metabolic syndrome group,
but not in both groups. This gave the two groups of proteins
shown in Tables 2(a) and 2(b). Another analysis was con-
ducted to see which altered proteins were common to both
obese groups compared to the control samples. This is
a shorter list with several proteins that suggest avenues
for further research. For example, S6K (ribosomal protein
S6 kinase) is substantially deceased in both obese groups.
This protein is involved in the phosphorylation of IRS-
1 (insulin receptor substrate-1) under the inﬂuence of
TNF-alpha [32]. In rats and mice, it is proposed that thisHuman Genomics and Proteomics 9
phosphorylation pathway leads to inﬂammation and insulin
resistance in obesity [33, 34]. However, it may not be quite
that straightforward since, in both patient groups, S6K
was decreased. Another protein, SWI/SNF-related, matrix-
associated, actin-dependent regulator of chromatin, is a co-
activator/repressor along with Brd2, of pancreatic cell func-
tion [35]. Disruption of Brd2 function causes obesity in
mice.Evenseeminglyunrelatedproteins,suchasspleenfocus
forming virus (SFFV) proviral integration oncogene spi1,
may be connected to the problem of insulin resistance. In
a study by Nishigaki et al., cells infected with spleen focus
forming virus exhibited Akt kinase activation [36]. Akt is
upstream in the signal transduction pathway of S6K.
A fourth protein that should be considered is the andro-
gen receptor. Expression of the androgen receptor is altered
in both groups. This seems like a reasonable event since it
has been reported that testosterone levels in women (and
men) can be greatly altered in the obese and metabolic status
[37–40]. However, there seems to be a major gender dif-
ference in the inﬂuence of androgens. While testosterone is
often elevated in obese women [39, 41], it is usually de-
pressed in obese men [38]. We did not analyze data from
obese men in this study. It is interesting that the mean levels
of the androgen receptor are elevated in the obese group and
decreased in the metabolic syndrome group. These examples
illustrate how proteins that seem to be unrelated may be
important in understanding the pathology of obesity.
4.2. Analysis of the Plasma Proteome without Clinical Bias. In
the unbiased analysis, the data were analyzed without pre-
conceived clinical groupings. The proteins were analyzed
using an unsupervised clustering methodology. It was ex-
pected ap r i o r ithat the Fob and FMS groups would cluster
into two separate groups. However, this was not the case.
The parameter that seemed to have the greatest correlation
with the cluster results was the HOMA value. Seven out of
nine patients in the group that we have designated, the High
HOMA group, had values above 4.0. In contrast, all patients
in the Low HOMA group had values less than 4.0. This is an
arbitrarycut-oﬀ,butitservestoquantifyaspeciﬁcparameter
that distinguishes the two groups that the clustering analysis
recognizes.
One of the aspects of altered protein expression that was
analyzed by this approach was the change in the insulin re-
ceptor pathways. Although metabolic syndrome is a diagno-
sisbasedonmultiplefactors,Grundyandcolleagues[42,43],
among others, have proposed that insulin resistance alone
can provide a mechanism for most of the consequences of
metabolic syndrome. Analysis of three longitudinal studies
by Cameron et al. [44] suggests that central obesity, as as-
sessedbywaistcircumference,precedestheappearanceofthe
other factors of metabolic syndrome. A more reﬁned mea-
sure of obesity, the umbilical waist-to-height ratio, predicts
the likelihood of insulin resistance and correlates well with
elevated HOMA-IR (r = 0.58, P<0.0001) in a study by
Guntsche et al. [45]. Once insulin resistance is established,
many of the criteria deﬁning metabolic syndrome begin
to manifest. For example, insulin resistance is associated
with increased sympathetic nervous activity, but blunted
sympathetic nervous system responsiveness [46]. This sym-
pathetic nervous activity has been linked to left ventricular
hypertrophy and may predict future renal injury [47]. Ab-
normalities in the cellular physiology and biochemistry of
the endothelium of the vascular wall have also been at-
tributed to insulin resistance. In studies of New Zealand
obese mice, a strain with the characteristics of increased
insulin resistance, increased visceral fat, and increased blood
pressure, it was observed that nitric synthase activity was
decreased.Inaddition,superoxideproductionwasincreased,
and increased inﬂammatory Mac-3+ cell inﬁltration was
measured [5]. For these reasons, the ﬁrst of the pathways
studied in detail was the insulin receptor signaling pathway.
As outlined in Results (see Figure 3), binding of insulin
to the insulin receptor initiates a number of phosphory-
lation events that include phosphorylation of the insulin
receptor substrate, SHC adapter proteins, and the Grb2-
associated binder-1 protein. One of the more important
targets of insulin activation is phosphatidylinositol-3-kinase.
Downstream events include Akt activation and the sub-
sequent activation of nucleotide phosphodiesterase (PDE)
which results in lower cAMP levels. Lowered cAMP levels
lead to decreased activity of hormone sensitive lipase and
decreased lipolysis. Thus, one can see that alterations can
have eﬀects at the level of modulation of energy stores and
at the level of protein synthesis. The diﬀerences between the
high HOMA group and the low HOMA are not large, but
with a complex system such as the insulin receptor signal
pathway, it can be imagined that small diﬀerences may be
suﬃcienttodisruptnormalregulatoryprocessestotheextent
that these changes have important clinical consequences.
5. Conclusions
Based on our analysis of this limited number of patients, it is
clearthatproteomicanalysisoftheplasmaproteomeofobese
adolescents has the potential to yield valuable information
concerning the underlying changes in the protein expression
and metabolic changes that give rise to the phenotypic man-
ifestations of the phenomenon known as metabolic syn-
drome. Our study is obviously limited by the small number
of patients. The next challenge in this project is to increase
the number of subjects and to widen the study to evaluate a
larger cross-section of both female and male patients. Thus
the data from this study, although promising, because of
the small numbers should be considered preliminary and a
project to extend and expand the investigation is warranted.
The ﬁnding that the proteome signature appears to group
subjects into those with and those without insulin resis-
tance may be extremely important in understanding the
pathophysiology of obesity in these young individuals. It is
possible that interventions should be focused on increasing
insulinsensitivity,forexample,byincreasingaerobicexercise
and physical ﬁtness, rather than the more diﬃcult task of
targeting signiﬁcant weight loss.10 Human Genomics and Proteomics
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